Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function
- PMID: 16442912
- PMCID: PMC2771182
- DOI: 10.1016/j.ahj.2005.03.066
Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function
Abstract
Background: The association between higher New York Heart Association (NYHA) class and outcomes in patients with heart failure and preserved systolic function is not well known.
Methods: We performed a retrospective follow-up study of 988 patients with heart failure with ejection fraction > 45% who participated in the DIG trial. Using Cox proportional hazard models, we estimated risks and all-cause mortality, heart failure mortality, all-cause hospitalization, and hospitalization due to worsening heart failure during a median follow-up of 38.5 months.
Results: Patients had a median age of 68 years; 41.2% were women and 13.9%, nonwhites. Overall, 23.4% of patients died, and 19.9% were hospitalized because of worsening heart failure. Proportion of patients with NYHA classes I, II, III, and IV were 19.9%, 58.0%, 20.9%, and 1.2%, respectively, and 14.7%, 21.1%, 35.9%, and 58.3%, respectively, died of all causes (P < .001 for trend). Respective rates for heart failure-related hospitalizations were 14.2%, 17.1%, 32.5%, and 33.3% (P < .001 for trend). Compared with NYHA class I patients, adjusted hazard ratios (HRs) for all-cause mortality for class II, III, and IV patients were 1.54 (95% CI 1.02-2.32, P = .042), 2.56 (95% CI 1.64-24.01, P < .001), and 8.46 (95% CI 3.57-20.03, P < .001), respectively. Respective adjusted HRs (95% CI) for hospitalization due to heart failure for class II, III, and IV patients were 1.16 (0.76-1.77) (P = .502), 2.27 (1.45-3.56) (P < .001), and 3.71 (1.25-11.02) (P = 018). New York Heart Association classes II through IV were also associated with higher risk of all-cause hospitalization.
Conclusion: Higher NYHA classes were associated with poorer outcomes in patients with heart failure and preserved systolic function.
Figures


Similar articles
-
A propensity matched study of New York Heart Association class and natural history end points in heart failure.Am J Cardiol. 2007 Feb 15;99(4):549-53. doi: 10.1016/j.amjcard.2006.08.065. Epub 2006 Dec 28. Am J Cardiol. 2007. PMID: 17293201 Free PMC article.
-
A propensity-matched study of the association of physical function and outcomes in geriatric heart failure.Arch Gerontol Geriatr. 2008 Mar-Apr;46(2):161-72. doi: 10.1016/j.archger.2007.03.010. Epub 2007 May 25. Arch Gerontol Geriatr. 2008. PMID: 17532064 Free PMC article. Clinical Trial.
-
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).JACC Heart Fail. 2015 Jun;3(6):429-441. doi: 10.1016/j.jchf.2014.12.017. Epub 2015 May 14. JACC Heart Fail. 2015. PMID: 25982110
-
Digoxin remains useful in the management of chronic heart failure.Med Clin North Am. 2003 Mar;87(2):317-37. doi: 10.1016/s0025-7125(02)00172-4. Med Clin North Am. 2003. PMID: 12693728 Review.
-
MERIT-HF mortality and morbidity data.Basic Res Cardiol. 2000;95 Suppl 1:I98-103. doi: 10.1007/s003950070017. Basic Res Cardiol. 2000. PMID: 11192362 Review.
Cited by
-
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.Eur J Heart Fail. 2022 Oct;24(10):1892-1901. doi: 10.1002/ejhf.2652. Epub 2022 Aug 27. Eur J Heart Fail. 2022. PMID: 36054231 Free PMC article.
-
Insights into the Novel Cardiac Biomarker in Acute Heart Failure: Mybp-C.Life (Basel). 2024 Apr 16;14(4):513. doi: 10.3390/life14040513. Life (Basel). 2024. PMID: 38672783 Free PMC article.
-
Characterizing advanced heart failure risk and hemodynamic phenotypes using interpretable machine learning.Am Heart J. 2024 May;271:1-11. doi: 10.1016/j.ahj.2024.02.001. Epub 2024 Feb 7. Am Heart J. 2024. PMID: 38336159 Free PMC article.
-
Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis.Egypt Heart J. 2024 Aug 5;76(1):97. doi: 10.1186/s43044-024-00532-z. Egypt Heart J. 2024. PMID: 39101961 Free PMC article. Review.
-
Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).Circ Heart Fail. 2015 Jan;8(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.114.001300. Epub 2014 Dec 5. Circ Heart Fail. 2015. PMID: 25480782 Free PMC article. Clinical Trial.
References
-
- Scrutinio D, Lagioia R, Ricci A, Clemente M, Boni L, Rizzon P. Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart Association classification, cardiopulmonary exercise testing, two-dimensional echocardiography and Holter monitoring. Eur Heart J. 1994;15:1089–95. - PubMed
-
- Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen LS. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J. 1994;15:303–10. - PubMed
-
- Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23:1861–6. - PubMed
-
- Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical